A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety and Pharmacokinetics of Intravenous VX-993 in Healthy Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Medical Information
- Phone Number: 617-341-6777
- Email: medicalinfo@vrtx.com
Study Locations
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- ICON Lenexa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2), inclusive
- A total body weight of more than (>) 50 kg
- Nonsmoker or ex-smoker for at least 3 months before first dose of the study drug
Key Exclusion Criteria:
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug.
- Any condition possibly affecting drug distribution, metabolism, or excretion
Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part A: Single Ascending Dose (SAD)
Participants will be randomized to receive a single dose of different dose levels of VX-993.
|
Solution for IV administration.
|
|
Experimental: Part B: Multiple Ascending Dose (MAD)
Participants will be randomized to receive multiple doses of different dose levels of VX-993.
The dose levels will be determined based on the data from Part A.
|
Solution for IV administration.
|
|
Placebo Comparator: Placebo Part A
Participants will be randomized to receive placebo matched to VX-993.
|
Solution for IV administration.
|
|
Placebo Comparator: Placebo Part B
Participants will be randomized to receive multiple doses of placebo matched to VX-993.
|
Solution for IV administration.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Day 1 up to Day 16
|
Day 1 up to Day 16
|
|
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Day 1 up to Day 43
|
Day 1 up to Day 43
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-993
Time Frame: Pre-dose up to Day 16
|
Pre-dose up to Day 16
|
|
Part B: Maximum Observed Plasma Concentration (Cmax) of VX-993
Time Frame: Pre-dose up to Day 43
|
Pre-dose up to Day 43
|
|
Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-993
Time Frame: Pre-dose up to Day 16
|
Pre-dose up to Day 16
|
|
Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-993
Time Frame: Pre-dose up to Day 43
|
Pre-dose up to Day 43
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- VX23-993-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.